In a report released yesterday, from Zhongtai Securities maintained a Buy rating on Innovent Biologics, with a price target of HK$134.50. The company’s shares closed yesterday at HK$89.70.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Currently, the analyst consensus on Innovent Biologics is a Strong Buy with an average price target of HK$124.33.
The company has a one-year high of HK$109.10 and a one-year low of HK$69.55. Currently, Innovent Biologics has an average volume of 13.95M.
